Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
about
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerMolecular biology of lung cancerMolecular biology of lung cancer: clinical implicationsMolecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersLung cancer: epidemiology, etiology, and preventionThe biology and treatment of EML4-ALK non-small cell lung cancerSomatic mutations of the epidermal growth factor receptor and non-small-cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issuesOptimizing the management of advanced non-small-cell lung cancer: a personal viewNew molecularly targeted therapies for lung cancerMucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar featuresOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsIntegrative analysis of multiple gene expression profiles with quality-adjusted effect size models.The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysisGene aberrations for precision medicine against lung adenocarcinomaGene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposureInterplay between Cellular and Molecular Inflammatory Mediators in Lung CancerCirculating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerLigand-Independent EGFR SignalingMolecular landscape of pancreatic cancer: implications for current clinical trialsMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularNew modalities of cancer treatment for NSCLC: focus on immunotherapyEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerGenetically engineered mouse models of pancreatic adenocarcinomaUtility of small biopsies for diagnosis of lung nodules: doing more with lessThe pivotal role of pathology in the management of lung cancerImproving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agentsIn vitro and in vivo models for analysis of resistance to anticancer molecular therapiesSystemic therapies for pancreatic cancer--the role of pharmacogeneticsThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerFragment Length of Circulating Tumor DNAStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerMolecular pathology of non-small cell lung cancer: a practical guide.Molecular pathology of lung cancer: key to personalized medicine.Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
P2860
Q24201207-31461769-E03A-4118-BC4E-6359DEDAD43DQ24606677-54799CE6-88C8-41E2-96B2-4BA15743FC8AQ24610335-A6FC329A-A896-4BF4-B2BA-43F55D2F8AC4Q24611043-AA205C32-1A68-4E9A-8FE0-372CE7D5E473Q24630167-4D04C0B0-ED85-46A6-B1F1-725B64A3E846Q24632625-2DC26A63-E9EA-4249-B9A0-096236829C3CQ24648133-713D6E40-508F-4265-AEE1-0AFACA80968EQ24653036-739D4256-1DFB-4ACD-8C7F-77042E809B4EQ24656144-BCA8ECFE-D563-4323-93E5-88D14EE92622Q24680988-374E8402-4C8A-4867-A3FD-52135F35DB8EQ24683814-0CBA0035-8B70-4533-BCCA-A9F932742D14Q24810573-281091E3-A88B-40A9-99E4-BD6647115125Q24815430-1ECEF9D6-BE95-4656-822F-B2CD49A15CD1Q26741041-50723CAF-2AB2-465B-B0D6-BAE64842D5D3Q26749348-1450EA46-C98D-4547-B8FE-3D3A110ED5D5Q26764865-AE5A0B98-75DA-4301-BE61-5D67C0198E3CQ26768652-850835B5-9AFC-46AA-9AA9-305CDF024D37Q26775376-D6BCDA59-F4C8-4C68-9B03-9FD570F176AAQ26797495-3FE77B26-BE31-46D3-869A-EDFDE65B936EQ26824528-E20EFE54-3580-48B1-89B9-BBD03ADB36DCQ26828860-B6CDB538-4F5B-4C5B-BBAD-932649E99801Q26829161-327F44B3-03F9-4980-9952-E3A6B5559903Q26852507-07539D25-6DE8-421C-A00B-C7A47323C8ADQ26865779-8D444A6A-ACB9-4FC8-BA3E-D27B76927413Q27002973-208228F4-E8C6-4EA6-8996-A09AEDB87FB6Q27009328-3A323300-3B0B-4525-A15C-C060A9EDCA86Q27010437-8CEC1425-44C2-4595-9249-19810660037DQ27012453-9DAB87F6-ECC3-4F0F-A01F-2D3F2A273EEEQ27014174-B9F3D668-7B94-4333-9BBF-93C3AE3AC0DDQ27021716-80A5801D-88E3-4997-BE29-DF4E86F0EF46Q27021738-AEDF9B56-D22C-4E96-964E-27B2D50DD179Q27308628-E6BD4723-B228-4016-95EE-DC3AC5D57CDEQ27680966-16F22401-A496-4AE5-BD85-6DC369367819Q27690919-01C289BF-BF36-4D41-8042-9135639BA185Q27691299-91213DC5-BFCE-4124-8480-4AC66C7D7684Q27851566-5D3AE96F-3111-40DD-8536-0E0EE1B02094Q27851658-C9001C4E-EABD-4A79-ABE5-6E172CD5E96EQ27851720-9F3ADD2F-CA9B-4D0F-B7ED-DF1D8ED7597DQ27852078-C76E166A-5123-48AA-844F-3EA99ACB3E27Q27853236-105D3C35-6EB1-4357-AAC3-7CFB1EA3F1E5
P2860
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Clinical and biological featur ...... gene mutations in lung cancers
@ast
Clinical and biological featur ...... gene mutations in lung cancers
@en
type
label
Clinical and biological featur ...... gene mutations in lung cancers
@ast
Clinical and biological featur ...... gene mutations in lung cancers
@en
prefLabel
Clinical and biological featur ...... gene mutations in lung cancers
@ast
Clinical and biological featur ...... gene mutations in lung cancers
@en
P2093
P2860
P3181
P356
P1476
Clinical and biological featur ...... gene mutations in lung cancers
@en
P2093
Fujisawa T
P2860
P304
P3181
P356
10.1093/JNCI/DJI055
P407
P577
2005-03-02T00:00:00Z